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We report here homologous recombination (HR)-
mediated gene targeting of two different genes in
human iPS cells (hiPSCs) and human ES cells
(hESCs). HR-mediated correction of a chromoso-
mally integrated mutant GFP reporter gene reaches
efficiencies of 0.14%–0.24% in both cell types trans-
fected by donor DNA with plasmids expressing zinc
finger nucleases (ZFNs). Engineered ZFNs that in-
duce a sequence-specific double-strand break in
the GFP gene enhanced HR-mediated correction by
> 1400-fold without detectable alterations in stem
cell karyotypes or pluripotency. Efficient HR-medi-
ated insertional mutagenesis was also achieved at
the endogenous PIG-A locus, with a > 200-fold
enhancement by ZFNs targeted to that gene. Clonal
PIG-A null hESCs and iPSCs with normal karyotypes
were readily obtained. The phenotypic and biological
defects were rescued by PIG-A transgene expres-
sion. Our study provides the first demonstration of
HR-mediated gene targeting in hiPSCs and shows
the power of ZFNs for inducing specific genetic
modifications in hiPSCs, as well as hESCs.
INTRODUCTION
Human embryonic stem cells (hESCs) derived from blastocyst-
stage embryos can self-renew indefinitely in culture while retain-
ing their pluripotency (Reubinoff et al., 2000; Thomson et al.,1998). Recently, human somatic cells have been successfully
reprogrammed into induced pluripotent stem cells (iPSCs) that
exhibit unique characteristics similar to hESCs (Lowry et al.,
2008; Mali et al., 2008; Park et al., 2008; Takahashi et al.,
2007; Yu et al., 2007). Patient-specific iPSCs hold enormous
promise for personalized cell replacement therapy, as well as
for research of various human diseases. Full utilization of these
human pluripotent stem cells (hPSCs) will require the develop-
ment of efficient methods for performing gene targeting, a
sequence-specific and permanent genome modification that
exploits the cell’s ability to perform homologous recombination
(HR). Gene targeting by HR has played a critical role in genetic
studies of various systems, including the generation of kno-
ckout/knockin transgenic mouse models using mouse ESCs.
The efficiency of HR-mediated gene targeting in hESCs, ho-
wever, remains low even 10 years after its first report (Thomson
et al., 1998), with only few successful studies published to date
using the method that is routinely performed in mouse ESCs
(Costa et al., 2007; Davis et al., 2008; Di Domenico et al., 2008;
Irion et al., 2007; Ruby and Zheng, 2009; Urbach et al., 2004;
Zwaka and Thomson, 2003). Using standard plasmid-based
systems, the current HR rate is < 106 in karyotypically normal
hESCs and other nontransformed mammalian cells. Moreover,
to date, there has been no report on successful gene targeting
in hiPSCs. One reason that gene targeting in hPSCs is more diffi-
cult is because they grow poorly as single cells (a practice
required for selection of rare targeted clones), compared with
mouse ESCs. Thus, strategies that increase the efficiency of
gene targeting in hPSCs would improve both the therapeutic and
experimental potential of these cells.
Zinc finger nucleases (ZFNs) are engineered sequence-
specific nucleases consisting of a customized array of zincCell Stem Cell 5, 97–110, July 2, 2009 ª2009 Elsevier Inc. 97
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a nonspecific DNA endonuclease domain (Durai et al., 2005;
Porteus and Carroll, 2005). Each zinc finger domain recognizes
3–4 bp of DNA, and a three-finger ZFN recognizes a 9–10 bp
DNA sequence. When two ZFNs bind their cognate target
sequence in the proper orientation, the nuclease domain is
able to dimerize and create a sequence-specific double-
stranded break (DSB). The ZFN-induced DSB can then be re-
paired with high efficiency by either HR or error-prone nonho-
mologous end-joining (NHEJ), independent of a DNA template
for repair. Therefore, ZFNs induce a site-specific insertion or
deletion at the site of the break after NHEJ or a defined genetic
modification near the site of the DSB by HR with an exogenous
donor DNA fragment. ZFNs have been used to make site-
specific genomic modifications with high efficiencies in a variety
of cell lines and several small organisms (Carroll, 2008). A recent
study showed that ZFNs can enhance gene targeting in human
ES cells using integrase-defective lentiviral vectors (IDLVs) to
deliver both ZFN expression cassettes and an HR donor DNA
template (Lombardo et al., 2007). Limitations of this study,
such as lack of data by Southern blotting for confirming the
HR event and excluding random integration of the donor DNA,
have been noted by the authors of a recent review (Giudice
and Trounson, 2008). Another limitation of this work is that the
two hESC lines used are prone to karyotypic abnormalities after
prolonged culture (Cowan et al., 2004). Such abnormalities likely
contribute to their favorable growth characteristics in culture
and can affect gene-targeting efficiencies. Whether ZFNs might
induce chromosomal alterations and changes in growth param-
eters of targeted hESCs has not been reported. Although the use
of IDLVs reduces the rate of vector integration substantially, it
does not eliminate such integration events (Mali et al., 2008;
Nightingale et al., 2006).
In this study, we used a virus-free system to perform ZFN-
enhanced gene targeting at the endogenous PIG-A gene and
at a defective, chromosomally integrated enhanced green fluo-
rescent protein (EGFP) reporter gene in both hESCs and human
iPSCs (hiPSCs). The PIG-A gene is required for the retention of
dozens of glycosyl-phosphatidyl-inositol-anchored proteins
(GPI-APs) on the cell surface and is mutated in hematopoietic
stem cells from patients with the blood disorder paroxysmal
nocturnal hemoglobinuria (PNH). The defective, chromosomally
integrated EGFP reporter gene that we used in our studies
requires HR to reconstitute a full-length gene and thereby
restore fluorescence. We demonstrate that the transient ex-
pression of sequence-specific ZFNs significantly enhanced
HR (2400-fold increase) in hESCs and that we were able to
readily obtain PIG-A null hESCs by both HR and mutagenic
NHEJ. Importantly, we also show that these ZFNs enhance
gene targeting without detrimental effects on either cell karyo-
types or pluripotency. Moreover, we also provide the first
demonstration that ZFNs can enhance gene targeting in two
hiPSC lines by successfully performing targeted HR events at
both the PIG-A locus and a chromosomally integrated EGFP
reporter gene. The present study describes and validates
publicly available ‘‘open-source’’ reagents and protocols that
will enable researchers to use ZFNs to efficiently create or
correct specific mutations at their genes of interest in hiPSCs
and hESCs.98 Cell Stem Cell 5, 97–110, July 2, 2009 ª2009 Elsevier Inc.RESULTS
Using an EGFP Gene Reporter System to Optimize Gene
Targeting in hESCs
To enhance the efficiency of gene targeting in hESCs by nonviral
vectors, we developed better methods for plasmid delivery and
for selection of rare transgenic hES clones. First, we established
an immortalized feeder cell line (W3R) that expresses Wnt3a to
promote hESC growth and coexpresses three drug-resistant
genes (Cai et al., 2007). The ability of W3R feeder cells that
support hESCs and are resistant to neomycin, hygromycin B,
and puromycin allowed us to efficiently select rare clones of
transfected hESCs expressing one of three drug-resistant genes:
NeoR, HygroR, or PuroR. Second, we optimized methods for
delivering plasmid DNA into hESCs using the Amaxa’s improved
electroporation method called nucleofection (Cai et al., 2007).
Using this strategy, hESCs can be transfected with > 50% effi-
ciency, and stable ESCs can be generated at a rate of 105 (Cai
et al., 2007; Hohenstein et al., 2008). In this study, we used these
optimized methods for plasmid delivery and selection to further
improve gene targeting in hESCs.
To assess the efficiency of HR-mediated gene targeting in
hESCs, we established a mutated GFP gene-based reporter
system, similar to one previously described and used in somatic
human cells (Porteus, 2006; Porteus and Baltimore, 2003). In this
improved version, the EGFP gene was used to achieve a brighter
GFP signal as compared to the GFPmut1 gene (Yang et al., 1996)
used in the previous studies. A 35 bp DNA fragment containing
a stop codon was inserted into the EGFP sequence, 12 bp
downstream of a site for which we had previously generated
ZFN pairs (Pruett-Miller et al., 2008). This mutated EGFP*
cassette was inserted into a lentiviral vector that we designated
EGIP* (Figure 1A). This EGIP* vector enables the creation of
a chromosomally integrated EGFP* target sequence by lentiviral
transduction in a variety of cell types, including hESCs. We also
constructed a donor template plasmid called tGFP, which
contains a truncated EGFP DNA. HR between the transfected
tGFP donor and the integrated EGFP* target results in the recon-
stitution of a full-length EGFP gene without the insertion, and its
gene expression restores GFP fluorescence. In 293T cells that
can be transfected very efficiently by either lipofection or nucle-
ofection, GFP+ correction rate was low (7 per 106 cells) when
cells were transfected by tGFP alone (Figure S1A available on-
line). Cotransfection of the same reporter 293T cells with tGFP
and two plasmids expressing ZFNs targeting a site in the
EGFP gene (Pruett-Miller et al., 2008) led to an increase in the
level of GFP+ cells to 3% (Figures S1B and S1C): a > 4000-
fold enhancement (Figure S1A). The percentage of GFP+ popu-
lation remained stable over 2 weeks after transfection, indicating
minimal cytotoxicity of ZFNs used in these experiments
(Figure S1D).
We next used the EGFP* HR system in hESCs after stable inte-
gration of the EGIP* reporter vector. Using conditions that we
had previously established for nucleofection of hESCs (Cai
et al., 2007), we were able to achieve a transient transfection effi-
ciency of 50%–70% for multiple hES lines, each bearing a stably
integrated EGIP* reporter vector (data not shown). Following
transfection of the tGFP donor DNA (Figure 1A), we measured
EGFP gene correction in hESCs (harboring the EGFP* reporter)
Cell Stem Cell
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(A) Scheme of the EGFP gene correction strategy. An enhanced GFP gene was mutated (EGFP*) by the insertion of a 35 bp fragment containing a translational
stop codon and aHind III site positioned 12 bp downstream of the GFP ZFN target site. The defective EGFP(*) transgene was delivered and integrated into human
cells by a lentiviral vector called EGIP*. For EGFP gene correction, a repair donor (tGFP) containing 50 truncated EGFP coding sequence was cotransfected with
two plasmids expressing a pair of GFP-targeting ZFNs (GFPZFN1 and GFPZFN2). If HR-mediated repair occurs, expression of the wild-type EGFP gene will be
restored. Arrows below the corrected EGFP gene represent primers used to detect the restored full-length EGFP gene.
(B) Fluorescence microscopy of EGFP gene correction with ZFNs in H9-EGIP* hESCs at day 7 postnucleofection.
(C) FACS analysis showing that the efficiency of ZFN-mediated EGFP gene correction in H9-EGIP* is as high as 0.24% (gated on TRA-1-60+ hESCs). Inset shows
that no GFP+ cells are detected in 106 cells collected in the absence of GFP-specific ZFNs.
(D) Numbers of corrected GFP+ cells (per million of TRA-1-60+ hESCs) were monitored by FACS for 30 days. Three different ratios of donor:ZFNs were used at
5:2, 5:10, and 1:10. A ratio (w/w) of 1:10 is equivalent to a molar ratio of 1 donor DNA for 6.1 molecules of each ZFN.
(E) PCR amplification of wild-type EGFP gene using primers indicated in (A). H9-EGIP* template contains aHind III site; therefore, PCR product can be digested by
Hind III (sample 2). After ZFN-mediated HR, GFP+ cells were sorted and showed restoration of the wild-type EGFP gene without the Hind III site (1 and 3).
(F) H9 EGIP cells after ZFN-mediated HR show a normal karyotype (46, XY).
(G) H9 EGIP cells after ZFN-mediated HR maintain expression of pluripotency markers such as SSEA4, TRA-1-60, NANOG, and OCT4 after expansion by long-
term culture. Scale bar, 50 mm.
(H) Immunostaining of embryoid body (EB) formed by H9 EGIP cells after ZFN-mediated HR. Day 14 EB shows ectoderm (NESTIN), mesoderm (DESMIN), endo-
derm (AFP), and trophectoderm (TROMA-I) markers. Scale bar, 50 mm.
(I) Teratoma formation of H9 EGIP cells after ZFN-mediated HR. H&E staining indicates in vivo differentiation of ectodermal (n, neuroepithelial), mesodermal
(b, bone; c, cartilage), and endodermal (g, glandular epithelial) structures.Cell Stem Cell 5, 97–110, July 2, 2009 ª2009 Elsevier Inc. 99
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(A) Four combinations of ZFN pairs targeting the PIG-A gene were tested for their abilities to induce mutagenic NHEJ in H1 (XY) hESCs that constitutively express
GFP (GGFP). GGFP hESCs were first transfected by nucleofection with one of the four ZFN combinations (L1R1, L1R2, L2R1, L2R2) and expanded. At 17 days
after nucleofection, expanded cells were treated with 0.5 nM aerolysin and allowed to form colonies for 7 days (Chen et al., 2008). The number of surviving colo-
nies following aerolysin selection is shown.100 Cell Stem Cell 5, 97–110, July 2, 2009 ª2009 Elsevier Inc.
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mids. We observed that GFP+ cells in the hESC population at
a frequency of up to 0.24% with ZFNs, compared to < 106
without ZFNs, a > 2400-fold increase in the efficiency of HR in
hESCs (Figures 1B and 1C). The level of GFP+ cells among the
undifferentiated (TRA-1-60+) hESC population remained stable
for at least 1 month following transfection of ZFN expression
plasmids (Figure 1D). Correction of the EGFP* to the wild-type
EGFP gene sequence was confirmed by both restriction diges-
tion mapping and direct DNA sequencing (Figures 1E and S2).
Corrected GFP+ hESCs that had been obtained by ZFN-medi-
ated HR retained normal karyotype, morphology, and expres-
sion of pluripotency markers even after long-term culture (>50
passages) (Figures 1F and 1G). Upon induction, they can also
differentiate into three embryonic germ layers and trophoblast
lineages via embryoid body (EB) formation in vitro (Figure 1H).
When injected into immunodeficient mice, the corrected GFP+
cells formed teratomas containing cells representing all three
embryonic germ layers (Figure 1I). These data indicate that our
gene-targeting approach using transiently expressed ZFNs
had no detectable adverse effects on the genome or pluripo-
tency of hESCs.
Engineering and Validation of ZFNs Targeted
to the Endogenous PIG-A Gene in hESCs
Because ZFNs can be engineered to recognize specific target
DNA sequences, ZFN-enhanced gene targeting can potentially
be used at any endogenous gene of interest. Therefore, we
next wished to test whether ZFNs could enhance gene targeting
of an actual endogenous human gene and focused our efforts on
PIG-A, a gene that we had previously been unable to alter genet-
ically using conventional gene-targeting methods. To create
PIG-A-specific ZFNs, we used the oligomerized pool engi-
neering (OPEN) platform recently developed (Maeder et al.,
2008) and engineered four ZFN pairs for a site within the PIG-
A-coding sequence. We chose to target such a sequence
because we reasoned that mutation at that site would generate
an inactive PIG-A protein.
We validated the four OPEN ZFN pairs targeting the PIG-A
gene using a modified version of the EGFP* gene-targeting
system described above, which contained the PIG-A ZFN target
site inserted into the EGFP* gene, an approach similar to what
has been used in previous studies (Porteus, 2006; Porteus andBaltimore, 2003; Urnov et al., 2005). We found that all four
PIG-A ZFN pairs stimulated gene targeting by > 200-fold in
293T cells, with the L1/R2 pair showing the highest efficiency
(Figure S3). We next tested these validated PIG-A ZFN pairs in
hESCs by determining their ability to induce mutations in the
endogenous PIG-A gene by mutagenic NHEJ repair of the
ZFN-induced DSB. We used male (XY) hESCs such as H1 so
that only one PIG-A gene (on the X chromosome) would need
to be mutated to generate a phenotypic effect. Null mutants of
PIG-A result in a loss of GPI-APs and, in turn, the resistance of
targeted cells to aerolysin-mediated cell killing (Chen et al.,
2008). It is important to note that PIG-A and GPI-APs have
been shown to be dispensable for the growth of undifferentiated
hESCs in culture (Chen et al., 2008). We utilized the aerolysin
selection method to enumerate rare PIG-A null mutations and
compared the activities of four PIG-A ZFN pairs in human
H1-derived GGFP ESCs. The best pair of ZFNs (L1/R2) identified
in the 293T EGFP* reporter assay also generated the greatest
number of PIG-A mutant clones, creating 28 aerolysin-resistant
colonies per 6 3 106 cells selected (Figure 2A).
One aerolysin-resistant hESC clone (called ‘‘GNAR’’) was
chosen for further characterization. GNAR grew similarly to the
parental cells from which it was derived, retained a normal karyo-
type, and displayed morphology and markers unique to hESCs
(Figures 2B and 2C). DNA sequencing of the targeted region re-
vealed deletion of 7 bp overlapping with the ZFN target sites,
resulting in a frameshift mutation and a premature stop codon
(Figure 2D). The PIG-A mutation in GNAR cells abolished the
cell-surface expression of GPI-APs, such as CD59 (Figure 2E)
and alkaline phosphatase (APase) (Figure 2F), as expected.
The loss of GPI-APs in GNAR cells could be rescued by introduc-
tion of a PIG-A transgene, confirming that the defect in these
cells is solely due to the lack of PIG-A expression (Figure 2E).
Similarly, the loss of biological functions by GNAR hESCs can
be restored by the PIG-A transgene expression in three different
functional assays in vitro and in vivo (Figures 2G and 2I).
Efficient ZFN-Mediated Gene Targeting
of the Endogenous PIG-A Gene in hESCs
Using the validated PIG-A ZFN pair L1/R2, we sought to develop
a more efficient, precise, and generalizable method for gene tar-
geting of the PIG-A gene without the need to use aerolysin selec-
tion. Compared with NHEJ, HR is a more precise method to(B) One of the aerolysin-resistant colonies derived following expression of the L1 and R2 ZFN pairs was isolated and termed as GNAR. After expansion, GNAR
cells display unique hESC morphology and markers such as TRA-1-60 and NANOG.
(C) GNAR cells exhibit a normal karyotype (46, XY).
(D) DNA sequence in PIG-A exon 6 in GNAR cells, compared with that from parental GGFP (H1) hESCs. A 7 bp deletion (blue) in the coding sequence was found,
resulting in frameshift and a premature translational stop codon (red). The PIG-A ZFN target sites are underlined. A sequencing chromatogram of GNAR cells is
shown below the sequence alignment, with an arrow indicating the deletion site.
(E) FACS analysis showing that GNAR cells have lost the expression of GPI-APs such as CD59. This defect can be rescued by the introduction of exogenous
PIG-A cDNA (GNAR-PIGA). Dot plot was gated on GFP+ hESCs.
(F) GNAR cells show loss of GPI-APs such as alkaline phosphatase (APase) on the cell surface. Scale bar, 50 mm.
(G) BMP4-induced trophoblast lineage differentiation defect in GNAR cells indicated by loss of hCG-a expression. BMP4 treatment was carried out as described
previously (Chen et al., 2008).
(H) Rate of teratoma formation of GNAR ESCs with or without PIG-A transgene expression. Zero out of nine injections showed teratoma formation monitored up to
4 months. These defects can be largely rescued by exogenous PIG-A cDNA expression.
(I) Differential sensitivities of GNAR and GNAR-PIG-A hESCs. GNAR cells lack complement inhibitory proteins such as CD59 and CD55, whereas PIG-A cDNA
expression restored these GPI-APs on the cell surface. Under lower pH (pH = 6.4) that activates complement-mediated cell lysis, GNAR showed a significantly
increased cell death monitored by Annexin V staining, compared with the GNAR-PIG-A cells or ESCs under normal pH (7.4, upper rows).Cell Stem Cell 5, 97–110, July 2, 2009 ª2009 Elsevier Inc. 101
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Thus, to inactivate the PIG-A gene by HR-mediated mutagenic
insertion, we constructed a donor vector (called ‘‘PHD’’) in which
a PGK-HygroR expression cassette was placed between two
PIG-A homology arms (Figure 3A). Successful HR-mediated tar-
geting will result in the insertion of the PGK-HygroR cassette into
the coding region in exon 6 of the PIG-A gene, thereby inactivat-
ing the PIG-A gene (Figure 3A). By contrast, random insertion of
PHD into transcriptionally active regions of the genome will also
result in the formation of HygroR ES clones but will not disrupt the
PIG-A gene. Thus, random insertions, unlike targeted insertions,
will result in the continued cell-surface expression of GPI-APs.
We transfected the PHD-targeting plasmid into H1-derived
GGFP hESCs in the presence or absence of vectors expressing
the L1/R2 ZFN pair to target the endogenous PIG-A locus.
Different ratios of donor versus ZFN expression vector DNA
were tested (Figure 3B), and following transfection, cells were
plated onto HygroR W3R feeder cells and selected for 12 days.
ES-like colonies emerged under each transfection condition,
and the number of colonies was quantified. In the absence of
ZFNs, we obtained 67 ± 11 HygroR colonies per 106 input cells
at transfection. The formation of HygroR colonies could be due
to either random integration or HR. With ZFNs, however, we ob-
tained significantly more HygroR colonies, ranging from 220 ± 54
to 395 ± 105 per 106 input cells (Figure 3B). After quantitation of
HygroR ES colonies, all of the cells were analyzed for the presence
or absence of GPI-APs such as CD59. When ZFNs were absent,
background levels of CD59 cells were detected (0.19%), indi-
cating that most, if not all, HygroR colonies resulted from random
insertion of the PHD donor into loci other than PIG-A. In contrast,
when ZFNs were present, CD59 cells were present at a high
frequency of up to 83% (Figures 3C and 3D). To confirm the tar-
geted insertion of PHD DNA into the PIG-A locus, we performed
PCR analysis using a pair of specific primers that only amplify
either the 50 or 30 junction of the predicted HR product (Figure 3E).
Targeted insertion products were abundantly detected in HygroR
cells obtained when ZFNs were used, but not in HygroR cells
obtained when ZFNs were absent (Figure 3E).To create knockout or knockin ESCs with a uniform genetic
background, it is critical to isolate clonal cell lines following HR
to ensure a homogenous population. With the improved HR effi-
ciency we observed with ZFNs, we tested whether we could
readily obtain PIG-A knockout clones (called ‘‘GPHR’’). From
12 HygroR hESC colonies, 6 clones (50%) were confirmed to
have undergone the predicted HR event at the PIG-A locus, as
determined by PCR to detect the targeted insertion (Figure 3F)
and by fluorescence-activated cell sorting (FACS) to detect the
loss of GPI-APs (Figures 3G and S4A). Two out of six clones
(#4 and #7) showed loss of CD59 in nearly all of the cells
(Figure 3G), thereby validating their clonality. The clonality and
the targeted insertion were further confirmed by Southern blot
(Figure 3H). Furthermore, both of these clones showed normal
karyotypes, undifferentiated hESC morphology, and expression
of unique hESC markers (Figures 3I, 3J, and S5). As expected,
the cell-surface expression of GPI-APs, such as APase, was
absent in these GPHR clones (Figure 3I). The altered phenotypes
of these GPHR clones, such as GPI-AP deficiency, could also be
rescued byPIG-A transgene expression (Figure S4B), confirming
that the GPI-AP deficiency in GPHR cells was solely due to PIG-
A gene knockout.
Gene Targeting in the MP2 hiPSC Line with or without
Using ZFNs
To our knowledge, there has been no published report to date
describing gene targeting by any method in hiPSCs. Therefore,
we investigated whether HR-mediated gene targeting could be
achieved in hiPSCs using the PIG-A and EGFP* systems with or
without the aid of ZFNs. The first of the two hiPSC lines that we
used is MP2, which has previously been shown to be pluripotent
(Mali et al., 2008). Using an optimized donor:ZFN ratio, we
observed GFP+ colonies emerge 5 days following transfection
of MP2 iPSCs harboring the mutated EGFP* template (Figure 4A).
Gene correction efficiency reached 0.14% when the GFP-
specific ZFN expression vectors were used in transfection, as
compared to < 0.0001% when ZFN expression vectors were
absent from the transfection (Figure 4B). These data demonstrateFigure 3. Knockout of the Endogenous PIG-A Gene in hESCs by ZFN-Mediated Homologous Recombination
(A) Scheme of PIG-A gene knockout using ZFNs targeting the coding sequence (gray) within exon 6. The DNA sequences of the two half ZFN sites (blue lines) are
shown in Figure S10. The HR donor (PHD) vector contains a PGK-HygroR-poly(A) expression cassette flanked by two arms of PIG-A homology sequences (2 kb
left + 2 kb right). In the PHD vector, a frameshift mutation and stop codon (red dot) upstream of the PGK-HygroR-poly(A) cassette were introduced to replace the
spacer sequence between the two ZFN sites. Two sets of PCR primers, indicated above the anticipated HR product (GPHR), were used to confirm the junctions of
targeted insertion. A DNA probe further downstream of the PIG-A locus and outside of the right arm of PHD was used for Southern blot analysis.
(B) After nucleofection and drug selection, the number of HygroR colonies per million input cells was calculated and compared among different ratios of do-
nor:ZFNs. The ratio (w/w) of 1:5 is equivalent to 1 donor for 4.2 DNA molecules of each ZFN. Six experiments were performed with the ratio of 1:5, and three
experiments were performed for the remaining ratios.
(C) Representative FACS analysis of CD59, a GPI-AP, expressed in the HygroR cell population after gene targeting. Dot plot was gated on GFP+ hESCs.
(D) Summary of CD59 population in the HygroR cells from two experiments, as analyzed in (C).
(E) PCR analysis of genomic DNA confirms that targeted integration (TI) occurred in HygroR cells only when ZFNs were used and when GPI-AP-deficient cells were
obtained. TI was detected by primer sets specific for 50 and 30 integration junctions as indicated in (A). An arbitrary genomic region (near PIG-A exon 4) was ampli-
fied as a positive DNA control.
(F) Twelve GPHR colonies were manually picked after HygroR selection following ZFN-mediated PIG-A knockout in GGFP cells. Six out of 12 showed targeted
integration (TI).
(G) Two of the 12 colonies, 4 and 7, were shown to have nearly complete loss of CD59.
(H) Southern blot analysis of genomic DNA afterMfe I digestion confirmed that these two clones (4 and 7) contain expected targeted insertion at the PIG-A locus.
Arrow indicates a longerMfe I band (5.7 kb, due to the PGK-HygroR insertion) instead of a 3.5 kb band in parental GGFP (see Figure 3A). G, GGFP parental hESCs.
(I) Staining of one of the two clones, 4 (GPHRc4). This clone lacks APase, a GPI-AP, on the cell surface but maintains undifferentiated hESC markers such as TRA-
1-60, OCT4, and NANOG. Scale bar, 50 mm. Similar data with clone 7 are shown in Figure S5.
(J) GPHRc4 (clone 4) cells exhibit a normal karyotype (46, XY). Similar data with clone 7 are shown in Figure S5.Cell Stem Cell 5, 97–110, July 2, 2009 ª2009 Elsevier Inc. 103
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(A) Microscopy of corrected (GFP+) MP2 iPSCs harboring the EGIP* reporter, 5 days after nucleofection with GFP-specific ZFNs.
(B) FACS analysis of EGFP gene correction in MP2 iPSCs with or without GFP-specific ZFNs. Dot plots were gated on TRA-1-60+ cells.
(C) PIG-A gene targeting in MP2 iPSCs with or without PIG-A-specific ZFNs was performed as described in Figure 3A using the 1:5 ratio of donor:ZFN DNA. After
nucleofection and hygromycin B selection, TRA-1-60+ (hiPS/hES) cells were analyzed for the presence or absence of CD59 (a GPI-AP). Representative FACS dot
plots are shown.
(D) Summary of FACS analysis of CD59 MP2 iPSC populations after PIG-A gene targeting from four independent experiments.
(E) PCR confirms the targeted integration into the PIG-A locus in MP2 iPSCs.that the ZFNs stimulate gene correction by at least 1400-fold in
human MP2 iPSCs. Because the mutated EGFP* target is not
present in every one of starting MP2 cells (since they are already
PuroR and full selection of the EGIP* integration by puromycin
resistance is not feasible), the number is likely an underestimate
(Figures 4A and 4B).
Next, we carried out ZFN-mediated gene targeting at the
endogenous PIG-A gene in MP2 hiPSCs (using the same
strategy employed for ESCs; see Figure 3). We anticipated that
the frequency with which we would obtain PIG-A-deficient
MP2 cells would be lower than what we achieved in the hESCs
because MP2 iPSCs are female (XX) in origin and thus contain
two copies of the PIG-A gene. It is unclear currently whether104 Cell Stem Cell 5, 97–110, July 2, 2009 ª2009 Elsevier Inc.the inactivated X chromosome inherited from the parental
IMR90 fibroblasts remains inactivated or is activated in MP2
iPSCs after reprogramming. In the latter case, targeting both
alleles of the PIG-A locus is required to generate a null pheno-
type. Following transfection of MP2 iPSCs with PHD donor
DNA with or without PIG-A-specific ZFN expression vectors,
we observed HygroR human ESC/iPSC-like colonies under both
conditions. In four independent experiments, we found that, on
average, 6.3 ± 0.7% of HygroR human cells are CD59 when
the PIG-A ZFNs were used (Figures 4C and 4D), compared
with background levels (<0.05%) when PIG-A ZFNs were not
used. The targeted integration of the PGK-HygroR DNA cassette
could also be easily detected in the ZFN-treated cells (Figure 4E).
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Gene to Generate GPI-AP-Deficient iPSCs
To better analyze and quantify HR-mediated PIG-A gene target-
ing, we also performed experiments in a well-characterized male
(XY) hiPSC line (Park et al., 2008). The hFib2-iPS5 cells were
derived from dermal fibroblasts of an adult male and were shown
previously to have a normal karyotype and full pluripotency (Park
et al., 2008). Similar to hESCs in early passages, the newly estab-
lished hFib2-iPS5 cells are delicate to expand and transfect. We
optimized conditions for efficient transfection of these cells in
the following ways. We initially followed the published method
and passaged them as clumps after partial dissociation by colla-
genase digestion (Park et al., 2008). However, the method yielded
poor transfection efficiencies using nucleofection or other trans-
fection techniques (data not shown). We found that trypsin or ac-
cutase treatment generated smaller clumps and single cells that
allowed us to achieve higher transient transfection efficiencies
(Figure S6), but the survival rate was much lower. We found that
treating with a ROCK inhibitor Y27632 before trypsin-mediated
cell dissociation significantly improved the colony-forming effi-
ciency of early passage hFib2-iPS5 (Figure S7), likely due to
enhanced survival of single cells/small clumps as found for hESCs
(Watanabe et al., 2007). The addition of Y27632 during and after
nucleofection further helped the attachment/survival of singlecells
or smaller clumps (<30 cells) in culture after transfection. With
these improvements, we transfected hFib2-iPS5 cells with the
PHD HR donor with or without the PIG-A ZFN expression vectors,
as we did for hESCs. Significantly more HygroR iPS colonies were
obtained if Y27632 was present (Figure 5A). When the HygroR
iPSCs were analyzed for the loss of GPI-APs such as CD59
(Figure 5B), up to 83% of the HygroR iPSCs were CD59 (average
45% ± 20%; Figure 5C) when ZFNs were used. In contrast, back-
ground levels (0.22% ± 0.04%) of CD59 cells were found when
ZFNs were absent, even though these iPSCs were also HygroR
(likely due to the PHD random integration). PCR analysis of har-
vested HygroR cells confirmed targeted integration of the PHD
DNA into the genome of hFib2-iPS5 cells when ZFNs were present
(Figure 5D). Without ZFNs, the resulting HygroR iPSCs were
neither CD59 nor showing the targeted integration (Figure 5D),
suggesting that they indeed resulted from random integration of
the PHD donor. Therefore, the PIG-A-specific ZFNs confer a >
200-fold increase in the efficiency of PIG-A gene targeting, equiv-
alent to that observed in hESCs (Figure 3D).
To molecularly characterize the targeting events, we randomly
picked nine HygroR iPSC colonies from treated cells after co-
transfection of PHD and ZFN-expression plasmids. We success-
fully expanded cells from eight colonies and analyzed them by
PCR to detect the targeted insertion (Figure 5E), by Southern
blot to confirm HR at the PIG-A locus (Figure 5F), and by FACS
analysis to confirm the loss of GPI-APs due to a PIG-A null muta-
tion (Figure S6). Five out of the eight hFib2-iPS5PIG-AHR (FPHR)
colonies (62.5%) that we analyzed had the targeted insertion at
the PIG-A locus (Figures 5E and 5F). Three of them (colonies
c1, c6, and c8) contained only the targeted PIG-A allele and
homogenously lacked GPI-AP expression (Figures 5F and S6),
suggesting a clonal origin for each picked colony. We found
that the donor DNA is present only in the targeted locus in these
three homogenous FPHR clones (Figure S8A). By a more sensi-
tive PCR-mediated method, we did not detect the presence ofthe ZFN DNA in the genome of the three clones (Figure S8B).
The homogenous iPSCs such as clone FPHR c1 lost the ex-
pression of GPI-APs but retained undifferentiated iPSC/ESC
morphology and the expression of pluripotency markers (Fig-
ure 5G). The differentiation potential of FPHRc1 iPSCs was
similar to thePIG-A null human ESCs based on the in vitro assays
described in Figure 2 (data not shown). Two randomly selected
iPS clones (c1 and c6) retained a normal karyotype after HR-
mediated gene targeting and expansion (Figure 5H). In summary,
successful correction of the mutated EGFP gene and mutation
of the endogenous PIG-A gene by HR show that ZFNs can
stimulate gene targeting in hiPSCs by at least several hundred-
fold. This degree of stimulation is sufficient to enable the isola-
tion of clonal populations of iPSCs with the desired genetic
modification.
DISCUSSION
The importance of making a specific genetic modification in
hPSCs has been widely recognized (Giudice and Trounson,
2008). The creation or correction of a specific mutation by HR-
mediated gene targeting ensures permanent genetic alterations,
a capability that will be of great utility in stem cell research and for
potential applications of hPSCs in therapeutic uses. In 2003 and
2004, two landmark papers demonstrated the feasibility of gene
targeting by HR in hESCs (Urbach et al., 2004; Zwaka and Thom-
son, 2003). Four more papers (Costa et al., 2007; Davis et al.,
2008; Di Domenico et al., 2008; Irion et al., 2007) in the past 2
years confirmed HR-mediated gene targeting in hESCs using
a plasmid-based delivery method. These studies collectively
demonstrated that HR is feasible in hESCs but is technically
challenging because of the low rate (<106) using standard tar-
geting strategies. These technical limitations have limited the
broad use of targeting in hPSCs, and a general approach that
increases the efficiency of targeting would increase the range
of experimental and potentially therapeutic uses of these cells.
One strategy to increase the rate of gene targeting in hPSCs is
to use highly specific ZFNs. ZFN-induced DSBs at specific
sequences have been used to stimulate targeting efficiencies
in a wide range of cell types and organisms (Carroll, 2008; Catho-
men and Joung, 2008) and were recently shown to stimulate
gene targeting in two hESC lines (Lombardo et al., 2007). The
strength and weakness of this pioneering paper that used
ZFNs (efficiently delivered by IDLV vectors) to achieve gene tar-
geting in multiple cell types, including hESCs, have been dis-
cussed comprehensively (Giudice and Trounson, 2008). Another
limitation of this study is that the two hESC lines used, HUES1
and HUES3, are prone to have karyotypic abnormalities after
prolonged culture (Cowan et al., 2004). Moreover, an analysis
of whether ZFNs might induce unwanted chromosomal rear-
rangements and changes in growth parameters was absent
(Lombardo et al., 2007). In the present study, we have demon-
strated that (1) ZFNs can be used to stimulate gene targeting
in hPSCs, including iPSCs, without inducing karyotypic changes
or changes in their pluripotent potential, (2) defined phenotypic
changes can be rationally created by the use of ZFN-mediated
gene targeting, (3) clonal cell lines with targeted genetic modifi-
cations can be derived and expanded, and (4) nonviral methodsCell Stem Cell 5, 97–110, July 2, 2009 ª2009 Elsevier Inc. 105
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These results are discussed in more detail below.
We used a virus-free DNA delivery system and successfully
targeted two different genes in karyotypically normal hESCs
and hiPSCs. Our studies were performed using novel ZFNs tar-
geting a disease-related gene (PIG-A) as well as the previously
described ZFNs targeting the EGFP gene (Pruett-Miller et al.,
2008). Using optimized ratios of donor DNA and ZFN-express-
ing plasmid vectors, as well as an improved method of DNA
delivery, our protocol allowed us to achieve high efficiencies
(stimulations of 200- to 2000-fold more than the rate without
ZFNs) of HR-mediated gene targeting in either creating a muta-
tion in the endogenous PIG-A gene or correcting a chromoso-
mally integrated mutant EGFP gene in both hESCs and iPSCs.
Despite using homology arms (a total of 2 kb) that would be
considered too short using standard targeting strategies (Di
Domenico et al., 2008; Suzuki et al., 2008), we achieved
a gene correction rate of 0.14%–0.24% in hESCs and hiPSCs
cotransfected with a pair of GFP-targeted ZFNs (Figures 1
and 4). Similarly, the gene-targeting efficiency at the endoge-
nous PIG-A gene was also high when a pair of ZFNs was
used together with a donor vector containing short (and thus
suboptimal) homology arms (a total of 4 kb). This approach
should be applicable to any gene of interest for which a pair
of highly active and specific ZFNs is generated and to other
methods for more efficient DNA delivery (Lombardo et al., 2007;
Suzuki et al., 2008).
We found that both hESCs and hiPSCs that had been targeted
using ZFNs had no karyotypic abnormalities and did not exhibit
any alteration in their pluripotent properties, even after extended
expansion to accumulate sufficient cells required for compre-
hensive cellular and molecular analyses. In addition, phenotypic
and biological defects of PIG-A null hESCs GNAR (created by
ZFN-mediated NHEJ) and GPHR (created by ZFN-mediated
HR) could be rescued by expression of a PIG-A transgene.
Together, these data suggest that undesired genome alterations
by a pair of high-quality and validated ZFNs are minimal.
However, we note that acute ZFN-mediated cell toxicity could
be observed when ZFNs were used at a higher concentration
with the nucleofection (Figure 3B) or the Lipofectamine 2000
transfection methods (data not shown). Long-term and off-target
effects of ZFNs remain to be fully characterized. Although majoralteration of genome due to off-target DSBs usually results in cell
death and elimination of affected cells, minor changes such as
small deletions and additions could be carried on in the surviving
population. It has been difficult to locate in the whole genome
a small alteration induced by off-target DSBs. It is now possible
to detect such abnormality by comparing parental and targeted
cell lines using advanced technologies such as genome-wide,
high-resolution SNP analysis and ideally whole-genome (deep)
DNA sequencing. In addition to using ZFNs that possess high-
quality zinc finger DNA-binding domains (as was done in this
report), two other strategies to reduce off-target effects of
ZFNs have been described. The first one uses modifications of
the nuclease domain to minimize homodimerization of ZFNs,
which may lead to cleavage at off-target sites (Miller et al.,
2007; Pruett-Miller et al., 2008; Szczepek et al., 2007). The
second one uses small molecules to attenuate the extent and
timing of ZFN expression (Pruett-Miller et al., 2009). It will be
interesting to determine the degree to which these strategies
minimize the off-target effects and toxicity of ZFNs when they
are utilized with ZFNs in hPSCs. The ability to expand a few
desirable ES or iPS clones unlimitedly alleviates the need to
achieve perfection in every single cell using ZFN-mediated HR.
Gene targeting at the level of hiPSCs and hESCs with unlimited
self-renewal capacity also allows for the full characterization of
genomic integrity before the use of the selected iPS and ES
clones that have undergone gene-targeting events. Taken
together, the studies reported here demonstrate that high-
quality ZFNs made by using the recently described OPEN plat-
form can induce highly efficient gene targeting in hESCs and
iPSCs with minimal toxicity and karyotypic alterations. The
OPEN method was developed by the Zinc Finger Consortium
(http://www.zincfingers.org) and accounts for context-depen-
dent DNA-binding activities of zinc fingers. OPEN ZFNs have
been previously used to modify three human genes (Maeder
et al., 2008), five zebrafish genes (Foley et al., 2009), and plant
genes (Maeder et al., 2008; Townsend et al., 2009). The results
of this report extend the number of endogenous human genes
modified by OPEN ZFNs and demonstrate that OPEN ZFNs
can be used in more than just somatic human cells. Importantly,
the reagents and protocols that are needed to make ZFNs by the
OPEN method are publicly available, and therefore, any inter-
ested academic laboratory can use the approach to engineerFigure 5. HR-Mediated PIG-A Gene Targeting in Male hiPSCs, Generating Clonal PIG-A Null iPSCs
(A) PIG-A knockout was performed in hFib2-iPS5 cells derived from adult (male) fibroblasts, using the strategy shown in Figure 3A. A nucleofection protocol
similar to that used for hESCs was carried out, except ROCK inhibitor (Y27632) was added. Mean and SEM of HygroR colonies per million of input cells from
three independent experiments are presented.
(B) FACS analysis of PIG-A knockout in hFib2-iPS5 cells with or without ZFNs in the presence of ROCK inhibitor Y27632. TRA-1-60+ (hiPS) cells were gated and
analyzed for the presence or absence of CD59. Representative dot plots are shown here.
(C) Comparisons of percentages of CD59 cells in HygroR hFib2-iPS5 cells after PIG-A gene targeting using various treatments, as described above. n = 3.
(D) PCR analysis confirms that HygroR hFib2-iPS5 cells contain targeted integration after ZFN-mediated HR treatment. F, parental hFib2-iPS5 cells.
(E) PCR analysis shows targeted integration in five out of eight hFib2-iPS5 colonies that we expanded and examined.
(F) Southern blot analysis detects the presence of the targeted (5.7 kb) and the wild-type (3.5 kb) PIG-A alleles (see a diagram in Figure 3A). The expected HR
product (the targeted insertion) is found in the same five colonies that are positive by PCR detection (E). Three of them (c1, c6, and c8) appear to be homogeneous
PIG-A knockout hFib2-iPS5 clones (FPHR) showing only the targeted allele (5.7 kb). Two (c2 and c3) contain both the targeted and the wild-type alleles. Because
the hFib2-iPS5 cells (male, XY) have only onePIG-A allele in the X chromosome, this is likely due to the fact that the colony picked after hygromycin selection is not
from a single clone and, instead, is from mixed cells. The remaining three HygroR colonies result from off-target insertion, showing only the wild-type PIG-A allele
as the parental hFib2-iPS5 cells (F). The Southern blot data are highly consistent with the pattern of GPI-AP expression in the eight analyzed colonies (Figure S6B).
(G) Staining of the FPHRc1 (PIG-A knockout) iPS clone shows loss of APase (a GPI-AP) on the cell surface, compared to the parental hFib2-iPS5 cells, but main-
tains the expression of pluripotency markers (TRA-1-60, SSEA-4, OCT4, and NANOG). Scale bar, 50 mm.
(H) FPHRc1 (left) and FPHRc6 (right) clones retain a normal karyotype (46, XY).Cell Stem Cell 5, 97–110, July 2, 2009 ª2009 Elsevier Inc. 107
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cell types such as hPSCs.
Our report provides the first demonstration of hiPSCs modified
by HR and demonstrates the feasibility and efficiency of an
approach that can be used for creating or correcting specific
mutations. Using the endogenous PIG-A gene and a chromoso-
mally integrated GFP gene as targets, we demonstrated that our
improved protocol of delivering gene-targeting donor and ZFN-
expressing plasmids works efficiently for hiPSCs as well as
hESCs. A major difference that we observed is that early
passage iPSCs, especially those passaged by collagenase as
cell clumps, survive poorly if they are harvested by trypsin as
smaller cell clumps or single cells required by the nucleofection
method. However, treating hiPSCs by adding a ROCK inhibitor
Y27632 before trypsin-mediated cell dissociation and during
the nucleofection significantly improved the survival of trans-
fected hiPSCs and the formation of HygroR colonies (Figure 5A).
The overall HR efficiency measured by the PIG-A gene targeting
in the newly established hiPSC lines is still lower than that in the
well-adapted hESC lines such as the H1/GGFP line. This is due,
at least in part, to the poor colony-forming efficiency of hFib2-
iPS5 cells, which is > 8- to 9-fold lower than that of H1/GGFP
hESCs (Figure S7). Despite all of the current limitations in cell
culture, resulting in a lower number of total HygroR colonies
per million of input hFib2-iPS5 cells, we are still able to generate
a cell population containing > 40% PIG-A-deficient cells after
drug selection and to isolate true PIG-A knockout iPS clones
from this XY iPSC line. Together with the data using a different
hiPS line (MP2), we showed for the first time that an endogenous
gene can be efficiently targeted in hiPSCs, demonstrating the
potential of using gene targeting in research and clinical applica-
tions of disease-specific hiPSCs. Possible future uses of gene
targeting in hiPSCs include (1) increasing the efficiency of
creating conditional alleles using the Cre-Lox system (Irion
et al., 2007), (2) correcting disease-causing mutations in X-linked
or autosomal genetic diseases, (3) using gene targeting to create
better models of human disease in hiPSCs, (4) using serial gene
targeting by HR to create precise biallelic modifications in auto-
somal genes or X-linked genes in female cells, and (5) using HR
to correct disease-causing mutations in patient-specific iPSCs
and using the genetically corrected cells to cure a disease, as
recently demonstrated in a mouse model (Hanna et al., 2007).
Previous studies have demonstrated that even genes that are
not transcriptionally active in undifferentiated hESCs, such as
MIXL1, CCR5, and FEZF2, can be successfully targeted (Davis
et al., 2008; Lombardo et al., 2007; Ruby and Zheng, 2009), as
has been observed in numerous cases of mouse ESC studies.
Enhancement of ZFNs on gene targeting of CCR5 has been
previously demonstrated in the two hESC lines used (Lombardo
et al., 2007). Thus, with the aid of ZFNs that greatly enhance
the HR efficiency in hESCs and hiPSCs, we are optimistic that
we will also be able to achieve gene targeting in iPSCs that are
not expressed in the undifferentiated state. The experimental
systems that we described here, i.e., the validated HR donor
constructs and ZFNs for two genes (EGFP and PIG-A) with
simply phenotypic readouts, will further help investigators to
optimize gene targeting in hiPSCs and hESCs with or without
a pair of ZFNs. Thus, our present study provides a solid founda-
tion for researchers interested in the efficient correcting or108 Cell Stem Cell 5, 97–110, July 2, 2009 ª2009 Elsevier Inc.mutating of a specific endogenous gene in both hiPSCs and
hESCs.
EXPERIMENTAL PROCEDURES
Culture of hESCs and hiPSCs
Human H1 and H9 ESC lines were obtained from WiCell Research Institute and
cultured as previously described (Chen et al., 2008; Yu et al., 2008). GGFP
derived from H1 ESCs with stable GFP expression by the lentiviral transduc-
tion (Dravid et al., 2005) was used in PIG-A gene targeting. MP2 iPS and
hFib2-iPS5 cells were passaged by collagenase and cultured as previously
described (Mali et al., 2008; Park et al., 2008).
Engineering of PIG-A-Specific ZFNs
ZFNs specific for a target site within the PIG-A coding sequence (Figure S10)
were engineered using the OPEN method as previously described (Maeder
et al., 2008). The top two of three zinc finger arrays for each half-site that
exhibited the highest levels of transcriptional activation in the bacterial two-
hybrid system were chosen for use as ZFNs. To construct ZFN expression
vectors for mammalian cells, XbaI-BamHI fragments harboring the engineered
zinc finger arrays were cloned into XbaI- and BamHI-digested pST1374 and
fused to the endonuclease domain in the vector (Maeder et al., 2008). A pair
of ZFNs targeting the GFP gene was previously described (Pruett-Miller
et al., 2008). The target site and amino acid sequences of these two GFP-
specific ZFNs are also shown in Figure S9. They are expressed from a similar
expression vector. Requests for OPEN ZFN reagents and protocols should
be directed to JKJ.
EGFP Gene Correction in 293T Cells
First, EGFP was mutated with either a 35 bp insertion (Figure S2) or a 41 bp
insertion containing PIG-A ZFN sites (Figure S3) and inserted into a lentiviral
vector with IRES-PuroR cassette (Figure 1A). After transduction and puromycin
selection, surviving cells containing EGIP* (termed 293T-EGIP* or 293T-EGIP*
PIGA) were used for EGFP gene targeting. The 2.53 105 293T-EGIP* or 293T-
EGIP*PIGA cells were plated in one 12-well coated with 0.1% gelatin 1 day
before lipofection. At the day of transfection, 1 mg of tGFP donor with various
amounts of ZFNs expression vectors was transfected using standard Lipofect-
amine 2000 protocol (Invitrogen). GFP+ cells started to show up at 2.5 days
after transfection and were monitored by FACS and microscopy thereafter.
EGFP Gene Correction in hESCs and hiPSCs
H9 hESCs were transduced with EGIP* (35 bp insertion) lentivirus and selected
with puromycin (1 mg/ml), and therefore, the starting population harbors EGIP*
template. The 5 3 106 H9-EGIP* cells grown on MEF feeder cells were har-
vested at 80% confluence with brief trypsin digestion and pipetting. Then,
the cells were resuspended in 100 ml Amaxa mouse ES nucleofection buffer
with various ratios of tGFP donor:ZFNs (e.g., 1:10 = 1 mg:10 mg) and trans-
fected using the Nucleofector II and preset programs such as A-23 (Amaxa).
Cells were replated 1:1 onto MEFs afterward, and GFP+ cells began to emerge
4–5 days later. For MP2 iPSCs that are already puromycin resistant, no puro-
mycin selection was done, and therefore, only a portion of the starting popu-
lation has the EGIP* template. The 3 3 106 mixed MP2-EGIP* cells (without
puromycin-mediated transgene selection) were used for EGFP gene correc-
tion with the same nucleofection settings as for H9-EGIP* cells.
PIG-A Gene Targeting in hESCs and iPSCs
GGFP hESCs, MP2 iPSCs, or hFib2-iPS5 cells (3–5 3 106) were transfected
with 4 mg of PIG-A-targeting donor (PHD) and various amounts of the L1/R2
ZFN pair (Figure S10). Transfected cells were then replated onto W3R feeders
(Cai et al., 2007) and selected with conditioned medium containing hygromycin
(10 mg/ml) for 12 days beginning from day 4 postnucleofection. In hFib2-iPS5
cell gene-targeting experiments, 10 mM ROCK inhibitor Y27632 (Watanabe
et al., 2007) was added for 1 hr prior to and 24 hr postnucleofection. Hygrom-
ycin-resistant colonies were counted after selection, and single colonies were
manually picked and expanded.
More details are provided in the Supplemental Data.
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Supplemental Data include Supplemental Experimental Procedures and 10
figures and can be found with this article online at http://www.cell.com/
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ACKNOWLEDGMENTS
We thank Sarah Dowey and the Johns Hopkins Hospital Prenatal Cytogenetics
Laboratory for professional karyotyping. We also thank three anonymous
reviewers for suggestions that helped us in revision. This work is funded in
part by the Stem Cell Research Foundation (S2005-026), Johns Hopkins Insti-
tute for Cell Engineering, and the NIH grant R01 HL073781 to L.C. J.Z. is sup-
ported by a Maryland Stem Cell Research Postdoctoral Fellowship Grant.
J.K.J.’s group is supported by the NIH (R01GM069906, R21RR024189, and
R21HL091808), the Cystic Fibrosis Foundation, and the MGH Pathology
Service. M.H.P.’s lab is supported by the state of Texas, NIH RO1
HL079295, and by a Career Development Award from the Burroughs-Well-
come Fund. G.Q.D. is an Investigator of Howard Hughes Medical Institute.
Received: February 25, 2009
Revised: April 24, 2009
Accepted: May 20, 2009
Published online: June 18, 2009
REFERENCES
Cai, L., Ye, Z., Zhou, B.Y., Mali, P., Zhou, C., and Cheng, L. (2007). Promoting
human embryonic stem cell renewal or differentiation by modulating Wnt
signal and culture conditions. Cell Res. 17, 62–72.
Carroll, D. (2008). Progress and prospects: Zinc-finger nucleases as gene
therapy agents. Gene Ther. 15, 1463–1468.
Cathomen, T., and Joung, J.K. (2008). Zinc-finger nucleases: the next gener-
ation emerges. Mol. Ther. 16, 1200–1207.
Chen, G., Ye, Z., Yu, X., Zou, J., Mali, P., Brodsky, R.A., and Cheng, L. (2008).
Trophoblast differentiation defect in human embryonic stem cells lacking
PIG-A and GPI-anchored cell-surface proteins. Cell Stem Cell 2, 345–355.
Costa, M., Dottori, M., Sourris, K., Jamshidi, P., Hatzistavrou, T., Davis, R.,
Azzola, L., Jackson, S., Lim, S.M., Pera, M., et al. (2007). A method for genetic
modification of human embryonic stem cells using electroporation. Nat. Pro-
toc. 2, 792–796.
Cowan, C.A., Klimanskaya, I., McMahon, J., Atienza, J., Witmyer, J., Zucker,
J.P., Wang, S., Morton, C.C., McMahon, A.P., Powers, D., et al. (2004). Deri-
vation of embryonic stem-cell lines from human blastocysts. N. Engl. J.
Med. 350, 1353–1356.
Davis, R.P., Ng, E.S., Costa, M., Mossman, A.K., Sourris, K., Elefanty, A.G.,
and Stanley, E.G. (2008). Targeting a GFP reporter gene to the MIXL1 locus
of human embryonic stem cells identifies human primitive streak-like cells
and enables isolation of primitive hematopoietic precursors. Blood 111,
1876–1884.
Di Domenico, A.I., Christodoulou, I., Pells, S.C., McWhir, J., and Thomson, A.J.
(2008). Sequential genetic modification of the hprt locus in human ESCs
combining gene targeting and recombinase-mediated cassette exchange.
Cloning Stem Cells 10, 217–230.
Dravid, G., Ye, Z., Hammond, H., Chen, G., Pyle, A., Donovan, P., Yu, X., and
Cheng, L. (2005). Defining the role of Wnt/beta-catenin signaling in the survival,
proliferation, and self-renewal of human embryonic stem cells. Stem Cells 23,
1489–1501.
Durai, S., Mani, M., Kandavelou, K., Wu, J., Porteus, M.H., and Chandrase-
garan, S. (2005). Zinc finger nucleases: custom-designed molecular scissors
for genome engineering of plant and mammalian cells. Nucleic Acids Res.
33, 5978–5990.
Foley, J.E., Yeh, J.R., Maeder, M.L., Reyon, D., Sander, J.D., Peterson, R.T.,
and Joung, J.K. (2009). Rapid mutation of endogenous zebrafish genes using
zinc finger nucleases made by Oligomerized Pool ENgineering (OPEN). PLoS
ONE 4, e4348.Giudice, A., and Trounson, A. (2008). Genetic modification of human embry-
onic stem cells for derivation of target cells. Cell Stem Cell 2, 422–433.
Hanna, J., Wernig, M., Markoulaki, S., Sun, C.W., Meissner, A., Cassady, J.P.,
Beard, C., Brambrink, T., Wu, L.C., Townes, T.M., et al. (2007). Treatment of
sickle cell anemia mouse model with iPS cells generated from autologous
skin. Science 318, 1920–1923.
Hohenstein, K.A., Pyle, A.D., Chern, J.Y., Lock, L.F., and Donovan, P.J. (2008).
Nucleofection mediates high-efficiency stable gene knockdown and trans-
gene expression in human embryonic stem cells. Stem Cells 26, 1436–1443.
Irion, S., Luche, H., Gadue, P., Fehling, H.J., Kennedy, M., and Keller, G.
(2007). Identification and targeting of the ROSA26 locus in human embryonic
stem cells. Nat. Biotechnol. 25, 1477–1482.
Lombardo, A., Genovese, P., Beausejour, C.M., Colleoni, S., Lee, Y.L., Kim,
K.A., Ando, D., Urnov, F.D., Galli, C., Gregory, P.D., et al. (2007). Gene editing
in human stem cells using zinc finger nucleases and integrase-defective lenti-
viral vector delivery. Nat. Biotechnol. 25, 1298–1306.
Lowry, W.E., Richter, L., Yachechko, R., Pyle, A.D., Tchieu, J., Sridharan, R.,
Clark, A.T., and Plath, K. (2008). Generation of human induced pluripotent
stem cells from dermal fibroblasts. Proc. Natl. Acad. Sci. USA 105, 2883–2888.
Maeder, M.L., Thibodeau-Beganny, S., Osiak, A., Wright, D.A., Anthony, R.M.,
Eichtinger, M., Jiang, T., Foley, J.E., Winfrey, R.J., Townsend, J.A., et al.
(2008). Rapid ‘‘open-source’’ engineering of customized zinc-finger nucleases
for highly efficient gene modification. Mol. Cell 31, 294–301.
Mali, P., Ye, Z., Hammond, H.H., Yu, X., Lin, J., Chen, G., Zou, J., and Cheng,
L. (2008). Improved efficiency and pace of generating induced pluripotent
stem cells from human adult and fetal fibroblasts. Stem Cells 26, 1998–2005.
Miller, J.C., Holmes, M.C., Wang, J., Guschin, D.Y., Lee, Y.L., Rupniewski, I.,
Beausejour, C.M., Waite, A.J., Wang, N.S., Kim, K.A., et al. (2007). An
improved zinc-finger nuclease architecture for highly specific genome editing.
Nat. Biotechnol. 25, 778–785.
Nightingale, S.J., Hollis, R.P., Pepper, K.A., Petersen, D., Yu, X.J., Yang, C.,
Bahner, I., and Kohn, D.B. (2006). Transient gene expression by nonintegrating
lentiviral vectors. Mol. Ther. 13, 1121–1132.
Park, I.H., Zhao, R., West, J.A., Yabuuchi, A., Huo, H., Ince, T.A., Lerou, P.H.,
Lensch, M.W., and Daley, G.Q. (2008). Reprogramming of human somatic
cells to pluripotency with defined factors. Nature 451, 141–146.
Porteus, M.H. (2006). Mammalian gene targeting with designed zinc finger
nucleases. Mol. Ther. 13, 438–446.
Porteus, M.H., and Baltimore, D. (2003). Chimeric nucleases stimulate gene
targeting in human cells. Science 300, 763.
Porteus, M.H., and Carroll, D. (2005). Gene targeting using zinc finger nucle-
ases. Nat. Biotechnol. 23, 967–973.
Pruett-Miller, S.M., Connelly, J.P., Maeder, M.L., Joung, J.K., and Porteus,
M.H. (2008). Comparison of zinc finger nucleases for use in gene targeting in
mammalian cells. Mol. Ther. 16, 707–717.
Pruett-Miller, S.M., Reading, D.W., Porter, S.N., and Porteus, M.H. (2009).
Attenuation of zinc finger nuclease toxicity by small-molecule regulation of
protein levels. PLoS Genet. 5, e1000376.
Reubinoff, B.E., Pera, M.F., Fong, C.Y., Trounson, A., and Bongso, A. (2000).
Embryonic stem cell lines from human blastocysts: somatic differentiation
in vitro. Nat. Biotechnol. 18, 399–404.
Ruby, K.M., and Zheng, B. (2009). Gene targeting in an HUES line of human
embryonic stem cells via electroporation. Stem Cells, in press. Published on-
line March 29, 2009. 10.1002/stem.73.
Suzuki, K., Mitsui, K., Aizawa, E., Hasegawa, K., Kawase, E., Yamagishi, T.,
Shimizu, Y., Suemori, H., Nakatsuji, N., and Mitani, K. (2008). Highly efficient
transient gene expression and gene targeting in primate embryonic stem cells
with helper-dependent adenoviral vectors. Proc. Natl. Acad. Sci. USA 105,
13781–13786.
Szczepek, M., Brondani, V., Buchel, J., Serrano, L., Segal, D.J., and Catho-
men, T. (2007). Structure-based redesign of the dimerization interface reduces
the toxicity of zinc-finger nucleases. Nat. Biotechnol. 25, 786–793.Cell Stem Cell 5, 97–110, July 2, 2009 ª2009 Elsevier Inc. 109
Cell Stem Cell
Gene Targeting in Human iPS and ES CellsTakahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K.,
and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human
fibroblasts by defined factors. Cell 131, 861–872.
Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergiel, J.J.,
Marshall, V.S., and Jones, J.M. (1998). Embryonic stem cell lines derived from
human blastocysts. Science 282, 1145–1147.
Townsend, J.A., Wright, D.A., Winfrey, R.J., Fu, F., Maeder, M.L., Joung, J.K.,
and Voytas, D.F. (2009). High-frequency modification of plant genes using
engineered zinc finger nucleases. Nature 459, 442–445.
Urbach, A., Schuldiner, M., and Benvenisty, N. (2004). Modeling for Lesch-
Nyhan disease by gene targeting in human embryonic stem cells. Stem Cells
22, 635–641.
Urnov, F.D., Miller, J.C., Lee, Y.L., Beausejour, C.M., Rock, J.M., Augustus, S.,
Jamieson, A.C., Porteus, M.H., Gregory, P.D., and Holmes, M.C. (2005). Highly
efficient endogenous human gene correction using designed zinc-finger
nucleases. Nature 435, 646–651.110 Cell Stem Cell 5, 97–110, July 2, 2009 ª2009 Elsevier Inc.Watanabe, K., Ueno, M., Kamiya, D., Nishiyama, A., Matsumura, M., Wataya, T.,
Takahashi, J.B., Nishikawa, S., Muguruma, K., and Sasai, Y. (2007). A ROCK
inhibitor permits survival of dissociated human embryonic stem cells. Nat. Bio-
technol. 25, 681–686.
Yang, T.T., Cheng, L., and Kain, S.R. (1996). Optimized codon usage and chro-
mophore mutations provide enhanced sensitivity with the green fluorescent
protein. Nucleic Acids Res. 24, 4592–4593.
Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L.,
Tian, S., Nie, J., Jonsdottir, G.A., Ruotti, V., Stewart, R., et al. (2007). Induced
pluripotent stem cell lines derived from human somatic cells. Science 318,
1917–1920.
Yu, X., Zou, J., Ye, Z., Hammond, H., Chen, G., Tokunaga, A., Mali, P., Li, Y.M.,
Civin, C., Gaiano, N., et al. (2008). Notch signaling activation in human embry-
onic stem cells is required for embryonic, but not trophoblastic, lineage
commitment. Cell Stem Cell 2, 461–471.
Zwaka, T.P., and Thomson, J.A. (2003). Homologous recombination in human
embryonic stem cells. Nat. Biotechnol. 21, 319–321.
